| 张慧,覃文办,江金玲,农艳华,黄美琪.替诺福韦对HBV BCP突变孕妇HBV母婴的疗效观察.[J].中南医学科学杂志.,2022,(1):78-81. |
| 替诺福韦对HBV BCP突变孕妇HBV母婴的疗效观察 |
| Effect of tenofovir on pregnant women with HBV BCP mutation |
| 投稿时间：2021-08-30 修订日期：2021-11-04 |
| DOI：10.15972/j.cnki.43-1509/r.2022.01.018 |
| 中文关键词: 乙肝病毒 病毒载量 基因突变 替诺福韦 |
| 英文关键词:hepatitis B virus viral load gene mutation tenofovir |
| 基金项目:崇左市科技计划项目(崇科FC2019004) 作者简介:张慧,硕士,副主任医师,研究方向为乙肝病毒母婴零传播,E-mail为limujun0771@126.com。 |
|
| 摘要点击次数: 566 |
| 全文下载次数: 341 |
| 中文摘要: |
| 目的观察替诺福韦对HBV基本核心启动子(BCP)突变孕妇HBV母婴的疗效。方法将慢性乙型肝炎孕妇分为治疗组(产前自愿接受治疗)和对照组(产前拒绝接受治疗)。根据是否发生HBV基本核心启动子(BCP)区1 762/1 764双位点突变,将治疗组、对照组孕妇分为突变株治疗组、野毒株治疗组、突变株对照组、野毒株对照组。突变株治疗组、野毒株治疗组分别于孕期第26周、第32周开始口服替诺福韦,分娩后即停药；突变株对照组、野毒株对照组均不用药,比较各组抗病毒疗效及乙肝母婴阻断效果。结果用药后6周、分娩前以及产后6个月突变株治疗组、野毒株治疗组HBV-DNA载量低于突变株对照组、野毒株对照组(P＜0.05)。新生儿出生时、7月龄及12月龄时突变株治疗组、野毒株治疗组HBV-DNA阳性率、HBsAg阳性率均分别低于突变株对照组、野毒株对照组,但组间差异无统计学意义(P＞0.05)。突变株治疗组与突变株对照组、野毒株治疗组与野毒株对照组新生儿身高、体质量、头围、Apgar评分比较,差异均无统计学意义(P＞0.05)。结论应用替诺福韦治疗可提高HBV BCP突变孕妇HBV母婴的疗效。 |
| 英文摘要: |
| To investigate the effect of tenofovir on pregnant women with HBV BCP mutation. MethodsThe pregnant women with virus B hepatitis were divided into the treatment groups (prenatal voluntary treatment) and the control groups (prenatal denial of treatment), and then divided into mutant treatment group, wild treatment group, mutant control group, and wild control group according to the occurrence of HBV basic core promoter (BCP) region 1 762/1 764 double site mutation. Tenofovir was taken orally in mutant treatment group and wild strain treatment group at the 26th and 32th weeks of pregnancy respectively, and the drug was stopped immediately after delivery. Mutant control group and wild virus control group were not treated, and the antiviral efficacy and mother-to-child blocking effect of hepatitis B in each group were compared. ResultsAt six weeks after treatment, before delivery and 6 months after delivery, the number of HBV-DNA copies in mutant treatment group and wild treatment group was lower than that in mutant control group and wild control group respectively (P＜0.05). At birth, 7 months and 12 months of age, the positive rates of HBV-DNA and HBsAg in the mutant treatment group and wild treatment group were lower than those in the mutant control group and the wild control group respectively, but there was no statistical significance between the groups (P＞0.05).There was no significant difference in neonatal height, body mass, head circumference and Apgar score between mutant treatment group and mutant control group, wild treatment group and wild control group (P＜0.05). ConclusionTenofovir treatment can improve the effect of HBV in pregnant women with HBV BCP mutation. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|